Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Completed 5Unknown 4Recruiting 4Active not recruiting 3Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Breast Neoplasms 17Ovarian Neoplasms 11Neoplasms 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Prostatic Neoplasms 6Neoplasm Metastasis 6Pancreatic Neoplasms 4Endometrial Neoplasms 4Neuroendocrine Tumors 3Glioma 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Recurrence 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Fanconi Anemia, Complementation Group D1 2Cholangiocarcinoma 2Uveal Melanoma 1Urogenital Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1SCLC,Extensive Stage 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Platinum-sensitive Ovarian Cancer 1

Interventions

pembrolizumab 25Paclitaxel 20Carboplatin 17Bevacizumab 12Specimen Handling 10Letrozole 10abemaciclib 7dostarlimab 6Taxes 6Blood Specimen Collection 6Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Fulvestrant 5Drug Therapy 5Doxorubicin 5Cisplatin 5Biopsy 5olaparib 4lenvatinib 4atezolizumab 4Radiotherapy 4Progestins 4Observation 4Nivolumab 4Megestrol Acetate 4Immunoglobulin G 4Gemcitabine 4trastuzumab deruxtecan 3palbociclib 3X-Rays 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Endometrial Neoplasms × olaparib × Clear all
NCT05554328 2026-06-03

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
165 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05255653 2026-05-15

RAINBO

Leiden University Medical Center

Phase 2/3 Recruiting
1,615 enrolled
Gynecologic

Endometrial Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
554 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡